Oramed Pharmaceuticals Inc.
Seite 1 von 40 Neuester Beitrag: 21.05.23 08:11 | ||||
Eröffnet am: | 28.03.07 13:46 | von: OttomanRos. | Anzahl Beiträge: | 988 |
Neuester Beitrag: | 21.05.23 08:11 | von: Jürgen1964 | Leser gesamt: | 259.362 |
Forum: | Hot-Stocks | Leser heute: | 138 | |
Bewertet mit: | ||||
Seite: < | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 40 > |
| |||||||||||||||||||||||
|
Diabetes is a serious chronic illness that represents a growing worldwide epidemic. According to the World Health Organization (WHO), the number of people suffering from diabetes has risen from 30 million in 1985 to almost 200 million in 2005, with projected figures suggesting that 370 million will be affected by 2030.
In the US alone, diabetes currently affects 20.8 million people. This represents 7.0 percent of the US population. Among them 35% to 45% need insulin injections to better control their diabetes.
According to analysts at Decision Resources, the total diabetes market (oral and insulin) was about US $11 billion in 2003. This market is expected to grow to US $14 billion by 2006, and the Type 2 diabetes therapeutic market is expected to exceed US $15.3 billion in 2013.
Growth of the diabetes market will be sustained through the continued expansion of the patient population due to aging, poor diet, conducting sedentary life style and excess body weight. The number of patients diagnosed is increasing due to routine screening and enhanced awareness.
Investment Considerations
Demand for alternative insulin delivery technologies is rising
Type 2 diabetes therapy market is expected to exceed US $15.3 billion in 2013.
The Research team is made up of experts involved in the development of insulin tablets and also in the conversion of other polypeptides including vaccinations and other hormones into per-oral forms g. tablets.
Effectiveness of insulin tablets is already proven successful on trials on animals at Hadassah University Hospital in Jerusalem.
Oral insulin tablets enable the delivery of insulin in a more physiological manner than by injection.
WKN : A0J3FG
ISIN : US68403P1049
Markt: Frankfurt
Kurzel : OJU.F
Preis: 0.50
5 Tages Prognose: 2.10
OJU.F ESGESCHAFT FIN UNTER PARI! LASSEN SIE SICH DIESE CHANCE NICHT
ENTGEHEN!
"In fact most parents took this in their stride.
0's marquee feature is "Reverse Ajax" (explained in a java. To enter,
create a video of up to three minutes that references Java ME or the
open-source phoneME technology used, and post it to YouTube. For example
one child moved from an IQ of 30 up to 70 and another from an IQ of 72
to 115.
Posted by: herkules on April 27, 2007 at 02:50 PM Sorry about that. In
the past the answer was to mould the pupil to the school - and if they
wouldn't bend, throw them out.
" This week's Spotlight is on Web Services Interoperability Technology
(WSIT) and Project Tango, two efforts focused on delivering
interoperability between Java EE and . As a benchmark, schools would
"Quality evaluation of any therapy requires more than one study. Mrs
Mason, of north London, is accused of professional misconduct for
filming staff and students without consent. Prizes include a Ericsson
K800 phone, Panasonic Blu-Ray DVD Player, an Amazon.
Prof Challis, retired professor of physics at the University of
Nottingham, said: "With a desktop computer, the transmitter will be in
the tower. setComponentZOrder() is called).
'I think, some of the frustration over Swing applications might stem
from those who call Swing methods from outside the event dispatch
thread, which then will have undeterminable behavior.
"They might say to their kids, 'Why are you doing your homework? This
session runs from April 30 through May 4. Instead of preparing pupils
for the high stakes tests at the end of each key stage, teachers' focus
would be on assessing when a child is able to move up one level in the
national curriculum grades. Finally, the newsletter offers a Tool Tip on
executing your application using Maven.
When special schools are included, 798,210 pupils in England's state
schools do not speak English as their first language.
And I should rehearse my BoF presentation. net podcast content in the
near future.
This contest seeks example of great Java ME applications or services.
The government said schools were required to promote community cohesion.
Yet this is a "softly, softly" revolution.
Tuesday September 9, 7:30 am ET
ORMD 0801 to be Tested on Type 2 Diabetic Volunteers
JERUSALEM, September 9 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB - News; http://www.oramed.com), a developer of oral delivery systems, announced today the signing of an agreement with ETI Karle Clinical Pvt. Ltd. (http://www.etiklinical.com), a clinical research organization (CRO) located in India, to conduct Phase 2B clinical trials on its oral insulin capsules.
The study is intended to evaluate the safety, tolerability and efficacy of ORMD 0801, Oramed's oral insulin capsule, on diabetic type 2 patients.
It is anticipated that the Phase 2B study will be conducted over several months starting in the first quarter of 2009, with approximately 60 subjects participating in the trial.
"Oramed has been able to demonstrate that ORMD 0801 has a good safety profile and effective on a small group of diabetes patients. This trial is intended to affirm that ORMD 0801 will perform to our expectation on a large group of type 2 diabetes patients," said Nadav Kidron, CEO of Oramed.
ETI Karle Clinical Pvt. Ltd is a Pan-Asian CRO, headquartered in Bangalore with a network of 60 clinical trial sites across all therapeutic areas, with access to 2 million patients, and 120 researchers.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Eric Rosenberg
Cell: +972-54-566-7713
Office: +972-2-566-0001
Email: eric@oramed.com
Media Contacts:
Ruder Finn Israel for Oramed
Matthew Krieger
Cell: +972-54-467-6950
Office: +972-2-589-2003
Email: matthew@oramed.com
ETI's Contacts:
Dr. M.V. Nagendran,
COO, ETI Karle Clinical Pvt. Ltd.
No. 72, Industrial Suburb,
Ward No. 10,
Near Ullas Theatre,
1st Block, Rajaji Nagar,
BANGALORE- 560 022, India
Cell: +91-9845010682
Office: +91-80-23371585
Email: nagendran@karlegroup.com
Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
Tuesday September 16, 8:00 am ET
ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed at Improving Glycemic Control in Adults With Type 2 Diabetes
JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB - News), a developer of oral drug delivery systems, announced today that it has launched pre-clinical trials of ORMD 0901, a GLP1-analog.
ORMD 0901 belongs to the Incretin family of drugs which helps to manage diabetes, including reduction in blood glucose levels and inhibiting glucagon secretion.
Incretins have been cited in causing regeneration of pancreatic insulin secreting cells, and in tissue protective properties including protection of the heart. GLP1 and analogs are associated with gradual weight loss, which is very desirable in diabetes patients.
"The launch of pre-clinical trials of ORMD 0901 and expansion of Oramed's platform marks the next strategic milestone for our company as we demonstrate the effectiveness of our oral delivery technology in yet another important family of polypeptide drugs for diabetes, that are until now only available in injection form," said Oramed CEO Nadav Kidron.
We plan to conduct the ORMD 0901 trials at Hadassah University Medical Center and they are expected to conclude by the end of 2008.
Oramed plans to launch phase 2b trials of ORMD 0801, its oral insulin capsule, in India in the first quarter of 2009.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Eric Rosenberg
Cell: +972-54-566-7713
Office: +972-2-566-0001
Email: eric@oramed.com
Media Contacts:
Ruder Finn Israel for Oramed
Matthew Krieger
Cell: +972-54-467-6950
Office: +972-2-589-2003
Email: matthew@oramed.com
Salut...
Interessantes Video....so gut wie Aktuell..
http://www.dailymotion.com/video/...pill-development-drug-trials_news
à bientôt
OC
à propos:Habe Heute Poste ich hier regelmässig....
bin rein zufällig auf dieses Forum gestoßen!
scheint sehr interessant zu sein diese Kapsel bzw. dieses Unternehmen.
Die Homepage gefällt mir sehr gut.
Mit welchem Kursziel rechnest Du?
Gruß reaaalist
Salut
Oramed ist dabei
http://bio12.mapyourshow.com/5_0/...7BA72E-BF65-ED97-50E0CA8CF5EA577E
à bientôt
OC
Salut reaaalist
Bin fröh hier dich zu lesen...
Dieser Forum braucht Leute mit Format wie Du
Ich hoffe wir lesen uns öfters...
Meine kursziel bei Oramed auf 1-2 Jahre--ý307 $...
Oramed ist 1 Technologie ....Kapsel...Die Anahme von Medikamente revolutionniere wird..
Alle mit Depot Wirkung oder Injektion....wie Grippe-Impfung...usw könnte wenn es klappt Oral genommen werden...
Die zukunft hat jetzt 1 Name.....ORAMED....
Ich vermute auch ab den Moment wo Oramed bei Nasdaq notiert wurde...Werden Die Grösse anstehen um dieser Firma zu übernehmen
à propos :Zulassung FDA für 4 Quartal 2012 geplant...Quelle :Video CEO..
à bientôt
OC
ist aber noch ein bisschen hin bis Mitte Juni!
2012 BIO International Convention
June 18-21, 2012 • Monday-Thursday
Boston Convention & Exhibition Center, MA
bin noch neu hier!
Wie fügt man denn einen Link ein? und wo sind die Smilies ?
ich probiere mal einen Link
Gruß r
hä, mit dem Link kriege ich nicht hin!
Salut reaaalist
Links Kopieren und einfügen.... geht von allein
Keine URL oder sonstiges...
Smilies habe keine Ahnung...
à bientôt
OC
1bisschen ...Schwer zu wissen wo du bist....Hin und her mit 2 Forum...
www.oramed.com
ah, Danke Occi
wozu steht denn unten rechts: Einfügen: Chart/Grafik Link
Gruß r
PS. Smilies habe ich gefunden
ja, so geht es!
Das sind ja schöne Aussichten!
Die FDA-Zulassung wird sicher den Kurs beflügeln.
Dann noch die Nasdaq-Notierung......
Aber Hallo!!!!!
Gruß r
http://www.bloomberg.com/video/91238322/
der CEO beim Interview.
Gruß r
Moin
rege Diskussion bei i-hub :-)
mit Backofen-Video...
Gruß r
Salut
Video CEO von 24-01-2012
http://www.youtube.com/watch?v=tZkbApveCCc
à bientôt
OC
Nasdaq....?
Salut
Meine Meinung nach...Es ist besser ORMP in USA zu kaufen..
Spread in Ffm,Stu,Berlin sind nicht zu verstehen...
à bientôt
OC
Salut Oramedist/in
Naja...Bin bei Wallstreet-online gesperrt...
Dann poste ich eben z.Zeit ..Hier..
Meine Meinung über Oramed..
Oramed ist 1 Kapsel (Géllule) die die Gastro-Sekret aushält und dann ihre Wirkstoof durch die Venae Portae im leber ablaggert...
Wichtig ist m.M.nach (und es ist meine Meinung)..oramed ist 1 Technologie...Könnte mann vergleiche wie 1
Neuer Medikämentöse transportsmittel...
Dieser könnte Medikamentöse verabreichung revolutionnieren...z.B medikament die bis jetzt durch Injektion erfolgt..Ich denke an Impfung z.B Grippe usw...
Wenn mann dieser Tatsache von Augen hat...wird bewüsst welche Potential Oramed hat..
Natürlich es ist nur m.Meinung...und vielleicht vor Nasdaq und FDA zulassung könnte noch den R/S
1ý18 kömmen wie am HV 2011 beschlossen war...Also...
Alle investiert Viel Glück...
Diese Posting ist keine Kauf oder Verkauf...Blablabla..
à propos:Sorry falls 1 paare grammatikale Fehler dabei sind...Bin von 1 andere Stern (Frz.)
à bientôt
OC
Salut reaaalist....
Habe gelesen.....Merci...
(Keine Ahnung wie hier smilies ....ist auch egal...)
à bientôt
OC
à propos:Falls 1 mitleser der ami´s Sprache sehr gut versteht ,soll sich melde auch per BM...Hatte 1 paar frage...weil ich Ami´s sprache,nicht so gut kennen.Danke